Page last updated: 2024-09-03

l 158809 and up 269-6

l 158809 has been researched along with up 269-6 in 4 studies

Compound Research Comparison

Studies (l 158809)	Trials (l 158809)	Recent Studies (post-2010) (l 158809)	Studies (up 269-6)	Trials (up 269-6)	Recent Studies (post-2010) (up 269-6)
137	0	7	15	4	0

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (75.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (25.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Goldberg, MR; Greenlee, WJ; Irvin, JD; Prendergast, K; Smith, RD; Timmermans, PB; Wexler, RR	1
Giridhar, R; Murumkar, P; Naik, P; Yadav, MR	1
Caussade, F; Cazes, M; Cloarec, A; Delchambre, C; Versigny, A; Virone-Oddos, A	1
Cazes, M; Cloarec, A; Provost, D; Versigny, A	1

Reviews

2 review(s) available for l 158809 and up 269-6

Article	Year
Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. Journal of medicinal chemistry, 1996, Feb-02, Volume: 39, Issue:3 Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Humans; Receptors, Angiotensin; Structure-Activity Relationship	1996
Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective. Bioorganic & medicinal chemistry, 2010, Dec-15, Volume: 18, Issue:24 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; Humans; Losartan	2010

Other Studies

2 other study(ies) available for l 158809 and up 269-6

Article	Year
In vitro pharmacological characterization of UP 269-6, a novel nonpeptide angiotensin II receptor antagonist. Fundamental & clinical pharmacology, 1995, Volume: 9, Issue:2 Topics: Adrenal Medulla; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta; Binding, Competitive; Biphenyl Compounds; Dose-Response Relationship, Drug; Imidazoles; In Vitro Techniques; Losartan; Male; Muscle, Smooth, Vascular; Pyrimidines; Radioligand Assay; Rats; Tetrazoles	1995
In vivo pharmacological characterization of UP 269-6, a novel nonpeptide angiotensin II receptor antagonist. European journal of pharmacology, 1995, Sep-15, Volume: 284, Issue:1-2 Topics: Administration, Oral; Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Decerebrate State; Dogs; Dose-Response Relationship, Drug; Heart Rate; Imidazoles; Injections, Intravenous; Losartan; Male; Pyrimidines; Rats; Rats, Sprague-Dawley; Species Specificity; Tetrazoles; Vasoconstrictor Agents	1995

Article

Year

In vitro pharmacological characterization of UP 269-6, a novel nonpeptide angiotensin II receptor antagonist.

Fundamental & clinical pharmacology, 1995, Volume: 9, Issue:2

Topics: Adrenal Medulla; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta; Binding, Competitive; Biphenyl Compounds; Dose-Response Relationship, Drug; Imidazoles; In Vitro Techniques; Losartan; Male; Muscle, Smooth, Vascular; Pyrimidines; Radioligand Assay; Rats; Tetrazoles

1995

In vivo pharmacological characterization of UP 269-6, a novel nonpeptide angiotensin II receptor antagonist.

European journal of pharmacology, 1995, Sep-15, Volume: 284, Issue:1-2

Topics: Administration, Oral; Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Decerebrate State; Dogs; Dose-Response Relationship, Drug; Heart Rate; Imidazoles; Injections, Intravenous; Losartan; Male; Pyrimidines; Rats; Rats, Sprague-Dawley; Species Specificity; Tetrazoles; Vasoconstrictor Agents

1995